Printer Friendly

PHARMACEUTICAL RESOURCES REACHES AGREEMENT TO SETTLE INVESTIGATION BY SECURITIES AND EXCHANGE COMMISSION

 PHARMACEUTICAL RESOURCES REACHES AGREEMENT TO SETTLE
 INVESTIGATION BY SECURITIES AND EXCHANGE COMMISSION
 SPRING VALLEY, N.Y., March 18 /PRNewswire/ -- Pharmaceutical Resources, Inc. (NYSE, PSE: PRX) ("PRI") announced today that it had reached an agreement with the Securities and Exchange Commission to conclude and settle the commission's investigation of PRI's subsidiary, Par Pharmaceutical, Inc.
 Pursuant to the settlement, PRI, without admitting or denying any of the allegations made by the commission, consented to the entry of an order enjoining it from future violations of the federal securities laws. The matter has been submitted to the court for approval. The settlement involves no civil fine or other sanction. The matters alleged by the commission that formed the basis for its investigation all occurred during the period from April 1986 to September 1988.
 Pharmaceutical Resources, Inc. is the parent company of Par Pharmaceutical, Inc., a manufacturer and marketer of prescription and over-the-counter generic drugs.
 -0- 3/18/92
 /CONTACT: Michael A. Swit or Richard J. Nadler of Pharmaceutical Resources, 914-425-7100/
 (PRX) CO: Pharmaceutical Resources, Inc. ST: New York IN: MTC SU:


KD-OS -- NY073 -- 9357 03/18/92 15:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:187
Previous Article:CATERPILLAR TO MAINTAIN MEDIA CENTER DURING UAW RALLY IN PEORIA, ILL.
Next Article:622 CONRAIL TRAINMEN ACCEPT VOLUNTARY SEPARATION
Topics:


Related Articles
PAR PHARMACEUTICAL SETTLES GOVERNMENT INVESTIGATION, AGREES TO PAY $2.5 MILLION IN FINES
PAR PHARMACEUTICAL SETTLES GOVERNMENT INVESTIGATION, AGREES TO PAY $2.5 MILLION IN FINES
PAR PHARMACEUTICAL SETTLES GOVERNMENT INVESTIGATION, AGREES TO PAY $2.5 MILLION IN FINES
PHARMACEUTICAL RESOURCES ANNOUNCES SETTLEMENT OF FINAL ASPECT OF SHAREHOLDER LAWSUITS
Copley Enters Plea
ICN Pharmaceuticals Settles 6-year Justice Department Investigation Of Disclosure Omission.
Barr and Kos in Settlement Discussions Regarding Niaspan(R) Patent Litigation; Court Agrees to Discontinue Further Proceedings to Allow Parties to...
AstraZeneca Announces Settlement With U.S. Government on Zoladex Investigation.
Watson and Unimed Pharmaceuticals, Inc. Settle Lawsuit Over AndroGel(R) Testosterone Gel.
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters